BCMA-Targeted Therapies in Multiple Myeloma

(2:24)

BCMA-targeted BiTEs for multiple myeloma

(8:13)

Hitting the BCMA Target in Multiple Myeloma

(55:48)

Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Pts w/RR Multiple Myeloma

(6:28)

Using BCMA-targeting agents in earlier lines of treatment for multiple myeloma

(1:38)

BCMA-Targeted Therapy in RRMM: Results From the DREAMM-1 Trial

(3:19)

BCMA-targeted Therapies and Multiple Myeloma

(3:24)

What is BCMA? #myeloma

(5:12)

Sequencing BCMA Myeloma Therapies

(58:19)

A 2023 Update on CAR-T Therapy in Myeloma with Dr. Craig Hofmeister

(1:3:49)

Cevostamab Shows Promise in Hard-to-Treat Multiple Myeloma: Early CAMMA 2 Trial Results

(7:49)

What Is BCMA

(3:19)

The future in multiple myeloma: BiTE immunotherapy, CAR-T, and immune checkpoint inhibitors

(21:41)

Bispecific Antibodies in Multiple Myeloma | Dana-Farber Cancer Institute

(23:13)

GPRC5D and FCRH5 Targeted Therapies in Myeloma

(1:2:21)

Phase I Study: Dual Targeting BCMA \u0026 CD19 FASTCAR-T for High-Risk Multiple Myeloma

(8:24)

What types of BCMA directed therapies are being explored in myeloma? #myeloma

(8:39)

BCMA-Targeted Therapy in RRMM: Future Challenges and BiTE

(3:47)

Future of BCMA-Targeted Therapies in Multiple Myeloma

(4:37)

Evaluation of Teclistamab in RRMM Patients Following Exposure to Other BCMA-Targeted Agents

(5:53)

What’s Next for BCMA-Targeted ADCs and CAR-T Therapy in RRMM?

(4:15)

Differentiating Types of BCMA-Targeted Therapies in RRMM

(4:5)

Sequencing BCMA-targeted agents in multiple myeloma

(2:19)

How do I treat patients with RRMM after failure of BCMA-targeted therapies?

(7:)

Sequencing BCMA-targeted therapies in myeloma

(1:29)

Incorporating BCMA-targeted CAR-T therapy in the frontline treatment of multiple myeloma

(53)

Integrating BCMA-targeted agents in earlier lines of therapy for R/R multiple myeloma

(2:31)

Using γ-secretase inhibitors to potentiate the efficacy of BCMA-targeted therapy in multiple myeloma

(3:28)

BCMA-Targeted CAR-Ts and Their Role in Late-Relapse Multiple Myeloma

(5:19)

Cevostamab in patients with triple-class refractory MM after prior BCMA-targeted bispecific antibody

(2:27)